Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRONE: Dolutegravir Impact on HIV-1 Reservoir
NCT02370979Phase 4Unknown
- Sponsor
- Strasbourg University Hospital
- Start
- Feb 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Strasbourg University Hospital. Primary endpoint: Change from baseline in Proviral HIV-1 DNA at Week 48. Status: unknown.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02370979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370979.